Literature DB >> 27027417

Surveillance rates for hepatocellular carcinoma among patients with cirrhosis, chronic hepatitis B, and chronic hepatitis C based on Japanese claims database.

Aya Hirata1,2, Takumi Hirata3, Yoshimitsu Takahashi2, Takeo Nakayama2.   

Abstract

AIM: Surveillance is recommended for patients with risk of hepatocellular carcinoma (HCC) such as viral hepatitis and liver cirrhosis (LC). Although populations are at higher risk in Asia, surveillance rates have not been evaluated in those countries. Therefore, we aimed to examine surveillance rates for HCC and to compare predictors for surveillance among each type of liver disease in Japan.
METHODS: We carried out an observational study using the medical claims data of Japan. A total of 4713 patients who were diagnosed with LC, hepatitis B virus (HBV), or hepatitis C virus (HCV) infection were followed for 12 months. We described surveillance rates in patients with HBV or HCV infection or non-viral LC and evaluated potential predictors for follow-up surveillance among them by using multivariable logistic regression analysis, in which we set explanatory variables as sex, age, medical facility, HBV or HCV infection, and LC.
RESULTS: The HCC surveillance rate during follow-up was 42.3% among patients with chronic viral hepatitis, 56.5% with viral cirrhosis and 26.0%, with non-viral LC. Significant predictors for follow-up surveillance were presence of LC and hospital visits. Hepatitis B virus-infected patients aged <50 years and HCV-infected patients aged ≥50 years were more likely to undergo exams, that is, different tendencies between HBV and HCV patients were shown.
CONCLUSIONS: Follow-up surveillance for HCC was not adequately carried out among patients at risk for HCC in Japan, despite of recommendation in guidelines. In future, methodological research might be needed to increase surveillance rates for HCC in patients with chronic hepatitis or those who received treatment at a clinic.
© 2016 The Japan Society of Hepatology.

Entities:  

Keywords:  Japan; hepatocellular carcinoma; medical claims data; practice guidelines; surveillance

Year:  2016        PMID: 27027417     DOI: 10.1111/hepr.12714

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  5 in total

1.  Tailored algorithms for hepatocellular carcinoma surveillance: Is one-size-fits-all strategy outdated?

Authors:  Nicolas Goossens; C Billie Bian; Yujin Hoshida
Journal:  Curr Hepatol Rep       Date:  2017-02-01

2.  Database analysis of patients with hepatocellular carcinoma and treatment flow in early and advanced stages.

Authors:  Keishi Akada; Noriyuki Koyama; Shigeru Taniguchi; Yuji Miura; Ken Aoshima
Journal:  Pharmacol Res Perspect       Date:  2019-06-20

3.  A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk.

Authors:  Catherine T Frenette; Ari J Isaacson; Irene Bargellini; Sammy Saab; Amit G Singal
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2019-07-11

4.  Data resource profile: JMDC claims database sourced from health insurance societies.

Authors:  Katsuhiko Nagai; Takashi Tanaka; Norihisa Kodaira; Shinya Kimura; Yoshimitsu Takahashi; Takeo Nakayama
Journal:  J Gen Fam Med       Date:  2021-02-14

5.  Hepatitis B virus X protein induces hepatic stem cell-like features in hepatocellular carcinoma by activating KDM5B.

Authors:  Xuyang Wang; Naoki Oishi; Tetsuro Shimakami; Taro Yamashita; Masao Honda; Seishi Murakami; Shuichi Kaneko
Journal:  World J Gastroenterol       Date:  2017-05-14       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.